Kite nails down TCR IP in new licensing pact

Kite Pharma ($KITE) has moved to cement its control of some of the IP behind its work on T cell receptor-based product candidates that zero in on MAGE A3 and A3/A6 antigens. It is paying the NIH an unspecified upfront and milestones in a deal that covers lung, pancreatic, gastric and breast cancers, among others. Kite has long had a very close working relationship with Steven Rosenberg at the NCI. Release

Suggested Articles

German researchers uncovered 28 antibodies that neutralize COVID-19 and are working with Boehringer Ingelheim to advance them into clinical testing.

Oragenics is ending a phase 2 study of its oral mucositis drug, yanking its IND application and switching its focus to a COVID-19 vaccine.

The vehicle, which Blackstone claims is the largest life sciences private fund, has committed close to $1 billion to companies including Alnylam.